Hims & Hers Q4: EPS Miss Deepens as Revenue Growth Accelerates
Hims & Hers Health (NYSE: HIMS) reported a fourth-quarter GAAP EPS of -$0.37, missing analyst expectations by $0.32. Revenue came in at $753.21 million, beating consensus by $23.09 million. The mixed results underscore a widening gap between the company’s top-line momentum and its bottom-line pressures, a dynamic investors are watching closely as the telehealth sector matures.
Revenue Beat Masks Margin Compression
The revenue beat, which represents a year-over-year increase of approximately 95% (based on prior-year revenue of $386.6 million), signals robust demand for its weight-loss and men’s health offerings. However, the EPS miss highlights significant cost pressures, including increased marketing spend and investments in GLP-1 supply chain capabilities. Gross margin for the quarter stood at 77.4%, down from 79.1% in the year-ago period, reflecting higher product mix costs and fulfillment expenses.
Operating expenses surged 68% year-over-year to $287.4 million, driven by a 72% jump in sales and marketing to $212.9 million. This aggressive customer acquisition strategy has paid off in user growth—active subscribers reached 2.2 million, up 44% from a year earlier—but it has yet to translate into profitability. The net loss widened to $190.2 million from $15.7 million in Q4 2023, a figure that includes a one-time impairment charge of $85.4 million related to a facility closure.
GLP-1 Expansion and Competitive Pressures
The company’s push into compounded GLP-1 medications (semaglutide and tirzepatide) is a double-edged sword. While the category has been a major growth driver, it faces regulatory scrutiny and competition from major pharma players like Novo Nordisk and Eli Lilly. Hims & Hers has priced its compounded alternatives at $199 per month (vs. branded price of $1,000+), a strategy that has resonated with price-sensitive consumers but also raises questions about long-term sustainability if compounding rules tighten.
In January, the FDA signaled a potential crackdown on compounded GLP-1s, citing safety concerns. Hims & Hers has responded by diversifying its portfolio, including launching a subscription service for oral ketamine (for depression) and expanding its dermatology line. Still, the GLP-1 segment accounted for roughly 30% of Q4 revenue, according to company filings.
Market Reaction and Valuation Outlook
Shares of Hims & Hers fell 8% in after-hours trading following the earnings release, reflecting investor disappointment over the EPS miss and the company’s guidance. For Q1 2025, management guided revenue to $540–$550 million, below the Street’s $561 million estimate, and expects adjusted EBITDA of $40–$50 million, implying continued margin pressure. The company also reaffirmed its full-year 2025 revenue target of $2.7–$2.8 billion, which would represent ~50% growth.
At current levels, HIMS trades at 4.2x forward sales, a premium to the broader healthcare sector (2.1x) but in line with high-growth digital health peers. The market is pricing in either a return to profitability or sustained top-line growth—both of which remain uncertain. Short interest stands at 12% of float, indicating significant bearish positioning.
What To Watch: The Next Earnings and Regulatory Signals
The key metric to watch is the company’s ability to convert its subscriber base into profitability. Specifically, the path to positive GAAP EPS will depend on whether marketing efficiency improves (i.e., customer acquisition costs decline) and whether GLP-1 supply chain costs stabilize. The next major catalyst is the Q1 2025 earnings report, expected in May, which will show whether the guidance cut is a one-off or a trend. Additionally, any FDA ruling on compounded GLP-1s could dramatically alter the revenue mix—a decision that could come at any time. If Hims & Hers can achieve adjusted EBITDA margins above 10% by Q3 while maintaining 40%+ revenue growth, the bear case weakens; otherwise, the stock may remain range-bound.
Comments are closed.